FWBI
Price:
$2.96
Market Cap:
$5.99M
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ...[Read more]
Industry
Biotechnology
IPO Date
2016-10-11
Stock Exchange
NASDAQ
Ticker
FWBI
According to First Wave BioPharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -28.76%. This represents a change of -83.24% compared to the average of -171.60% of the last 4 quarters.
The mean historical ROE of First Wave BioPharma, Inc. over the last ten years is -42.09%. The current -28.76% ROE has changed -31.68% with respect to the historical average. Over the past ten years (40 quarters), FWBI's ROE was at its highest in in the December 2020 quarter at 658.93%. The ROE was at its lowest in in the June 2023 quarter at -474.99%.
Average
-42.09%
Median
-320.31%
Minimum
-668.22%
Maximum
1.47%
Discovering the peaks and valleys of First Wave BioPharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 1.47%
Minimum Annual Increase = 0%
Minimum Annual ROE = -668.22%
Year | ROE | Change |
---|---|---|
2023 | -438.39% | -27.50% |
2022 | -604.68% | -180.06% |
2021 | 755.33% | -48.49% |
2020 | 1.47% | -533.70% |
2019 | -338.12% | 11.77% |
2018 | -302.50% | -54.73% |
2017 | -668.22% | 47.14% |
2016 | -454.14% | -377.98% |
2015 | 163.38% | Infinity% |
2014 | 0% | 0% |
The current ROE of First Wave BioPharma, Inc. (FWBI) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-95.92%
5-year avg
168.11%
10-year avg
-42.09%
First Wave BioPharma, Inc.’s ROE is greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Blue Water Vaccines, Inc. (-111.44%), greater than PaxMedica, Inc. Common Stock (-1151.68%), greater than Revelation Biosciences, Inc. (-243.91%), greater than Hillstream BioPharma, Inc. (-47249.59%), greater than Dermata Therapeutics, Inc. (-197.44%), less than Panbela Therapeutics, Inc. (545.45%), less than ContraFect Corporation (403.13%), less than SeaStar Medical Holding Corporation (323.08%), greater than Virios Therapeutics, Inc. (-130.35%), greater than ZyVersa Therapeutics, Inc. (-172.51%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), greater than Cardio Diagnostics Holdings, Inc. (-308.99%), greater than Sigilon Therapeutics, Inc. (-81.98%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Zura Bio Limited (-35.45%), greater than Apexigen, Inc. (-606.56%), greater than Phio Pharmaceuticals Corp. (-142.68%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Immix Biopharma, Inc. (-86.48%),
Company | ROE | Market cap |
---|---|---|
-112.11% | $3.06M | |
-111.44% | $3.41M | |
-1151.68% | $834.97K | |
-243.91% | $1.43M | |
-47249.59% | $4.17M | |
-197.44% | $2.08M | |
545.45% | $1.75M | |
403.13% | $1.72M | |
323.08% | $20.29M | |
-130.35% | $4.94M | |
-172.51% | $2.70M | |
-398.33% | $4.53M | |
-308.99% | $6.94M | |
-81.98% | $56.22M | |
32.93% | $109.78M | |
-35.45% | $230.86M | |
-606.56% | $9.57M | |
-142.68% | $2.25M | |
2.18% | $188.18K | |
-86.48% | $54.08M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like First Wave BioPharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like First Wave BioPharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is First Wave BioPharma, Inc.'s ROE?
How is the ROE calculated for First Wave BioPharma, Inc. (FWBI)?
What is the highest ROE for First Wave BioPharma, Inc. (FWBI)?
What is the 3-year average ROE for First Wave BioPharma, Inc. (FWBI)?
What is the 5-year average ROE for First Wave BioPharma, Inc. (FWBI)?
How does the current ROE for First Wave BioPharma, Inc. (FWBI) compare to its historical average?